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class I and class II histone deacetylases and
increases p21 levels in castrate-resistant prostate
cancer cells
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John P Biggerstaff3 and Jay Whelan1,4*Abstract
Background: Zyflamend, a mixture containing extracts of ten herbs, has shown promise in a variety of preclinical
cancer models, including prostate cancer. The current experiments were designed to investigate the effects of
Zyflamend on the expression of class I and II histone deacetylases, a family of enzymes known to be over expressed
in a variety of cancers.
Methods: CWR22Rv1 cells, a castrate-resistant prostate cancer cell line, were treated with Zyflamend and the
expression of class I and II histone deacetylases, along with their downstream target the tumor suppressor gene
p21, was investigated. Involvement of p21 was confirmed with siRNA knockdown and over expression experiments.
Results: Zyflamend down-regulated the expression of all class I and II histone deacetylases where Chinese goldthread
and baikal skullcap (two of its components) appear to be primarily responsible for these results. In addition, Zyflamend
up regulated the histone acetyl transferase complex CBP/p300, potentially contributing to the increase in histone 3
acetylation. Expression of the tumor suppressor gene p21, a known downstream target of histone deacetylases and
CBP/p300, was increased by Zyflamend treatment and the effect on p21 was, in part, mediated through Erk1/2.
Knockdown of p21 with siRNA technology attenuated Zyflamend-induced growth inhibition. Over expression of
p21 inhibited cell growth and concomitant treatment with Zyflamend enhanced this effect.
Conclusions: Our results suggest that the extracts of this polyherbal combination increase histone 3 acetylation,
inhibit the expression of class I and class II histone deacetylases, increase the activation of CBP/p300 and inhibit
cell proliferation, in part, by up regulating p21 expression.
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The use of herbs, botanicals and their bioactive compo-
nents have been shown to be effective in many tumor
cell lines in vitro and in vivo by inhibiting cell and tumor
growth. The use of herbal extracts in combination po-
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reproduction in any medium, provided the orsignificant activity when the effects of any single agent
are less robust [1,2]. Zyflamend (New Chapter, Inc.,
Brattleboro, VT) is a combination of the extracts of ten
herbs, many of which are used as nutrient supplements
(ginger, rosemary, turmeric, Chinese goldthread, holy
basil, Hu Zhang, barberry, oregano, green tea and basil
skullcap) (Table 1). It has been shown that Zyflamend
has anticancer properties in experimental models of
cancers, i.e., bone, skin, mouth, pancreas and kidney
[3-8]. In addition, Zyflamend has been shown to reduce
proliferation in a variety of prostate cancer (PrC) cellLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Composition of herbal extracts in Zyflamend and
relative concentration of individual herbs used in vitro





Chinese goldthread 5.1 4.1
Holy Basil 12.8 10.2
Hu Zhang 10.2 8.2
Barberry 5.1 4.1
Oregano 5.1 4.1
Green tea 12.8 10.2
Basil skullcap 2.5 2.0
Total 99.7 79.8
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and apoptosis [9-14]. Of particular interest to our la-
boratory is the effect of Zyflamend on castrate-resistant
PrC [9,10,15].
Histone deacetylases (HDACs) are a family of enzymes
associated with cancer risk. Post-translational modification
of histones, in particular the removal or addition of acetyl
groups on ε-N-acetyl lysine residues, play an important
role in epigenetic regulation of transcription. Acetylation
of the N-terminal tails of histones “relaxes” the chromatin
making it more accessible for binding by co-activating
factors. The result is an increase in gene expression.
In contrast, deacetylation results in a more compact
chromatin and transcriptional repression. Regulation
of acetylation is a balance between deacetylators and
acetylators [16]. HDACs in particular are important in
cancer biology by promoting proliferation, angiogenesis,
migration/metastasis, resistance to chemotherapy, and
inhibiting apoptosis and differentiation (as reviewed in
Ref [17]). Identification of HDAC inhibitors is therefore a
new therapeutic approach to treat cancer [18,19].
Eighteen different isoenzymes of HDACs have been
identified and are divided into 4 classes, I-IV. Class I
and II HDACs form complexes with multiple cofactors
for activation where histones are a primary substrate [20]
and have been targets for cancer therapies, including PrC
[21]. They appear to be particularly important in regu-
lating cell survival and proliferation [20,21]. Class I HDACs
(types 1, 2, 3, 8) are located almost exclusively in the
nucleus. Class II HDACs are subdivided where IIa (types
4, 5, 7, 9) has an N-terminal domain that regulates
shuttling between the nucleus and cytoplasm. Class IIb
HDACs (types 6, 10) are predominantly cytoplasmic and
their functions are less well established. In castrate-resistantPrC cells, HDAC1 is overexpressed compared with
androgen sensitive PrC cells [22] and HDAC4 is pre-
dominantly expressed in the nucleus of hormone re-
fractory cancer cells [23], while HDAC8 does not appear
to be expressed in PrC epithelial cells [24]. HDACs 1–4
have been shown to be involved in the repression of p21
expression [25-27]. HDAC6 is unique in that it contains
two catalytic domains that independently contribute to
its activity. HDAC6 is predominately found in the cyto-
plasm whose major substrates include α-tubulin and
Hsp90 [28-30]. HDAC6 over expression has been associ-
ated with a variety of cancer cell lines, including prostate
[30]. Class III HDACs (SIRT1-7) also require a unique
set of cofactors for activity that are distinctly different
from those involved with class I and II HDACs. They
are NAD-dependent, share homology to yeast Sir 2 family
of deacetylases and their primary targets are not histones
[16]. HDAC11 (class IV) is structurally related to class I
and II HDACs, but little is known about this HDAC.
The goal of this project was to better understand the
properties of the anticancer effects of the combination
of bioactives from Zyflamend. Our previous research
demonstrated that Zyflamend, when provided orally,
inhibited tumor growth using a xenograph model of
castrate-resistant PrC in vivo and these effects were
associated with inhibition of expression of HDACs 1
and 4 [9]. To better understand the effects of Zyflamend
on HDAC expression, we followed up our in vivo results
by investigating the broader effects of Zyflamend on the
expression of class I and II HDACs in the same model of
castrate-resistant PrC.
Prostate cancer is currently the most commonly diag-
nosed solid malignancy and has become the second
leading cause of cancer-related deaths in men in most
Western developed countries [31]. One in six men will
develop invasive prostate cancer in their lifetime [31].
Metastatic PrC is defined as the spread of PrC cells to
secondary sites (i.e., bone, lung, etc.). Once tumors
become metastatic, they are very difficult to treat, and
prognosis is poor with a 31% 5-year survival rate [32].
For the most part, PrC is temporarily responsive to
hormone deprivation therapy as prostate epithelial cells
are dependent on androgens for growth. While treatment
with hormone deprivation results in tumor regression and
clinical stabilization, the disease eventually relapses, with
invariable fatal results within two years. Therefore, a
critical barrier in treating advanced PrC is finding ef-
fective adjuvant treatments for castrate-resistant forms
of the disease. The CWR22Rv1 PrC cell line was chosen
for the experiments because it represents a late stage of
PrC [33] and our preliminary experiments using this cell
line in vivo linked Zyflamend treatment with HDAC
inhibition [9]. These cells can grow in the presence
or absence of androgens, produce prostate specific
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ceptor [33]. These critical factors are consistent with
PrC in patients whose disease has relapsed following an-
drogen ablation therapy as their tumors can grow in the
absence of androgens, typically have functional androgen
receptors and can produce PSA.
In this study, we investigated the effects of Zyflamend
on expression of class I and class II HDACs and down-
stream targets, such as the tumor suppressor gene p21.
This work was designed to explore some of the molecu-
lar mechanisms behind the anti-carcinogenic effects of
Zyflamend. This study was not designed to compare
Zyflamend with the pharmacokinetics of a variety of com-
mercially known HDAC inhibitors, although Zyflamend




Zyflamend (New Chapter, Brattleboro, VT) is derived
from the extracts of ten different herbs (w/w): holy basil
(Ocimum sanctum) (12.8%), turmeric (Curcuma longa)
(14.1%), ginger (Zingiber officinale) (12.8%), green
tea (Camellia sinensis) (12.8%), rosemary (Rosmarinus
officinalis) (19.2%), Hu Zhang (Polygonum cuspidatum)
(10.2%), barberry (Berberis vulgaris) (5.1%), oregano
(Origanum vulgar) (5.1%), baikal skullcap (Scutellaria
baicalensis) (2.5%), and Chinese goldthread (Coptis
chinensis) (5.1%). The total portion of extracts in Zyflamend
is 40% (Table 1). A detailed description and characterization
of the preparation of Zyflamend and quality assurance
of the mixture has been described previously [9].
Cell culture
Human prostate cell lines, RWPE-1, LNCaP, PC3 and
CWR22Rv1, were purchased from American Type Culture
Collection (Rockville, MD). PrEC cells (Lonza, Walkerville,
MD) were grown in Clonetics™ Bulletkit™ medium ac-
cording to the supplier’s instructions. RWPE-1 cells
were maintained in complete medium containing kera-
tinocyte serum free medium supplemented with bovine
pituitary extract (BPE) (0.05 mg/mL) and human re-
combinant epidermal growth factor (hEGF) (5 ng/mL).
LNCaP and PC3 cells were maintained in RPMI 1640
media (Life Technologies, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS) (Life Technologies,
Grand Island, NY) under an atmosphere of 5% CO2 at
37°C. Cells were harvested with the addition of 0.25%
trypsin with 0.02% EDTA during the exponential growth
phase. For the experimental treatments, CWR22Rv1 cells
were cultured in RPMI 1640 media supplemented with
0.05% fetal bovine serum containing Zyflamend or indi-
vidual herbal extracts (ginger, rosemary, turmeric, Chinese
goldthread, holy basil, Hu Zhang, barberry, green teaand baikal skullcap) (each supplied by New Chapter,
Inc, Brattleboro, VT) reconstituted in dimethyl sulfoxide
(DMSO) for cell proliferation assay, mRNA extraction and
protein isolation. For inhibitor experiments, CWR22Rv1
cells were pretreated with U0126 (Erk inhibitor) (Cell
Signaling Technology, Inc., Danvers, MA) at a dose of
2 μM for 30 minutes and subsequently treated with
Zyflamend (200 μg/mL) for 24 hr. For experiments
involving the general HDAC inhibitor TSA, TSA was
added to CWR22Rv1 cells at a concentration of 2 μM for
24 hours and compared to cells treated with Zyflamend
(200 μg/mL). In all experiments, 0.1% DMSO was used as
the vehicle control.
Cell proliferation
The MTT assay [3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide] (Andwin Scientific,
Addison, IL) was used to assess relative cell growth
and viability, following the manufacturer’s instructions
(Promega, Madison, WI). Cells (1 × 104 cells of RWPE-1,
LNCaP, and CWR22Rv1, and 5 × 103 cells of PC3) were
plated in 96-well plates in a volume of 100 μl culture
medium. The culture medium contained various concen-
trations of Zyflamend (0, 40, 80, 100, 150, 200 μg/mL) or
individual herbal extracts (10.2 μg/mL ginger, 15.4 μg/mL
rosemary, 11.3 μg/mL turmeric, 4.1 μg/mL Chinese gold-
thread, 10.2 μg/mL holy basil, 8.2 μg/mL Hu Zhang,
4.1 μg/mL barberry, 10.2 μg/mL green tea, 2.0 μg/mL
baikal skullcap; equivalent to those doses in 200 μg/mL
Zyflamend, Table 1). Cell proliferation was determined
at 0, 24, 48, 72, 96 hr post incubation. At each time
point, a mixture of MTT:complete medium (1:10, v/v)
was added and incubated at 37°C for 4 hr in a CO2
incubator (5%). Absorbance (at 540 nm) was measured
on a SpectraCount microplate photometer (Perkin Elmer
Inc, Waltham, MA).
BrdU incorporation assay
Cells (1 × 104 cells of CWR22Rv1) were plated in 96-well
plates and treated with various concentrations (0, 100,
150 and 200 μg/mL) of Zyflamend for 48 hr and followed
by a BrdU incorporation assay to assess relative DNA
synthesis following the manufacturer’s instructions (EMD
Biosciences, Inc., Darmstadt, Germany). After Zyflamend
treatment, cells were treated with BrdU for 4 hr and the
BrdU incorporation was measured on a FluoroCount
microplate photometer (Perkin Elmer Inc, Waltham, MA)
at a 340 nm excitation and a 460 nm emission.
Cellular and nuclear detection of p21 via
immunofluorescent imaging
CWR22Rv1 cells were seeded on cover slips in RPMI
1640 media supplemented with 10% FBS under an atmos-
phere of 5% CO2 at 37°C overnight. Before the treatment,
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with 0.5% FBS. For the observation of p21 and its nuclear
localization, the cells were pretreated with Zyflamend
(200 μg/mL) for 24 hr. After the treatment, the cells were
fixed using 2% paraformaldehyde for 15 min, followed by
blocking with 10% goat serum (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) for 1 hr, and anti-p21 antibody
(10 μg/mL) (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) overnight at 4°C. After washing with PBS, coverslips
were incubated with secondary antibody (10 μg/mL of
Alexa Fluor 488 goat anti-rabbit IgG) for one hour at
room temperature. Coverslips were mounted on glass
slides with Prolong Gold w/ DAPI Antifade reagent
(Invitrogen Corporation, Carlsbad, CA) and analyzed
by epifluorescence microscopy. Four dual-channel images
were captured from each sample using a 60x objective
lens. Image analysis was performed using NIS-Elements
software v3.1 (Nikon Instruments, Melville, NY). Mean
fluorescence intensity per cell was calculated by the fol-
lowing: [(total p21 fluorescence)/(nuclei count)]. To assess
p21 nuclear accumulation, p21 fluorescence was also
measured within discrete nuclear regions as defined using
a DAPI intensity threshold.
Down regulation of p21 by small interfering RNA
CWR22Rv1 (1.5 × 105 cells per well in 6-well plates, in
serum-free RPMI 1640 media) were transfected with val-
idated p21 small interfering RNA (siRNA) or Stealth™
siRNA negative control (Invitrogen, Carlsbad, CA) (100
pmole each) using Lipofectamine 2000™ transfection re-
agent (Invitrogen, Carlsbad, CA) following the manufac-
turer’s instruction. Six hr post transfection, cells were
cultured with RPMI 1640 media containing 10% FBS over-
night. After recovery, media was replaced with 0.05% FBS
media containing vehicle or Zyflamend (200 μg/mL) for
24 hr at 37°C. The total RNA was harvested for quantita-
tive real-time polymerase chain reaction (qRT-PCR) and
cell number was determined.
Overexpression of p21
pRc/CMV-p21 (Addgene Inc., Cambridge, MA), containing
full length wild-type p21 cDNA, was used to overexpress
p21. CWR22Rv1 cells (1.5 × 105 cells per well in 6-well
plates) were plated overnight. pRc/CMV-p21 or pRc/CMV
(empty vector) was transfected using Lipofectamine 2000™
reagent in serum-free RPMI 1640 media. Transfected cells
were selected by treatment for two weeks with neomycin
(50 μg/mL) and subjected to the MTT cell proliferation
assay. p21 protein expression in the transfected cells was
examined by Western blot.
RNA isolation and quantitative RT-PCR
Total RNA was isolated from CWR22Rv1 cells using
Trizol reagent (Invitrogen, Carlsbad, CA) followed bychloroform extraction. The aqueous phase was precipi-
tated in 100% isopropanol and the pellet was washed in
75% ethanol prior to re-suspension in RNase-free water.
Contaminating DNA was removed from RNA samples
using Turbo DNA free™ kit (Ambion, Inc. Austin, TX) and
then the concentration of total RNA was measured using
NanoDrop 1000™ (Thermo Scientific, Wilmington, DE).
Total RNA (2 μg) from each sample was mixed with
MultiScribe™ Reverse Transcriptase, RNase Inhibitor,
dNTP Mixture, random hexamers, RT buffer, MgCl2
solution and incubated at 25°C for 10 min, 48°C for
30 min and 95°C for 5 min to reverse transcribe to
cDNA using TaqMan reagent kit (Applied Biosystems,
Carlsbad, CA). cDNA samples were used for quantita-
tive RT-PCR (ABI Prism 7300 Real-Time PCR System,
Applied Biosystems, Carlsbad, CA). cDNA (0.7 μl) was
used as a template for qPCR amplification with primer
sets (2.5 μM) of p21 sense, 5′-TGGAGACTCTCAGGG
TCGAAAA-3′ and antisense, 5′- CCGGCGTTTGGAG
TGGTA-3′, p27 sense, 5′-CGGTGGACCACGAAGAG
TTAA-3′ and antisense, 5′-GGCTCGCCTCTTCCATG
TC-3′, HDAC1 sense, 5′-ACCGGGCAACGTTACGAAT-3′
and antisense, 5′-CTATCAAAGGACACGCCAAGTG-3′,
H DAC2 sense, 5′-TCATTGGAAAATTGACAGCATA
GT-3′ and antisense, 5′-CATGGTGATGGTGTTGAA
GAAG-3′, HDAC3 sense, 5′- TTGAGTTCTGCTCGC
GTTACA-3′ and antisense, 5′-CCCAGTTAATGGCA
ATATCACAGAT-3′, HDA4 sense, 5′-AATCTGAACC
ACTGCATTTCCA-3′ and antisense, 5′-GGTGGTTAT
AGGAGGTCGACACT-3′, HDAC5 sense, 5′-TTGGAG






Amplification was performed using a standard thermo-
cycle program beginning with an initial temperature
at 94°C for 1 min followed by 30 cycles of 94°C for
15 sec, 50°C for 30 sec and 72°C for 2 min. Each sam-
ple was examined in triplicate and the amounts of PCR
product were normalized with 36B4, 5′-TGCATCAGT
ACCCCATTCTATCA-3′ and 5′-AAGGTGTAATCCG
TCTCCACAGA-3′ as the internal control. The relative
amounts of all mRNAs were calculated using the
comparative CT method as previously described with
36B4 as the invariant control [34,35]. The relative
amounts of 36B4 and the various transcripts were cal-
culated using the following formula: relative amounts
of mRNA= 1/2(CT-Time X -CT-Time 0), where CT-Time X is the
CT number at one experiment time point, and CT-Time 0
is the CT number at time 0. The levels of 36B4 and the


































Figure 2 Effects of Zyflamend on BrdU incorporation in a
time- and dose-dependent manner. Cells were treated ± Zyflamend
at various concentrations (0, 100, 150 and 200 μg/mL) over 24 and
96 hr (n = 8/time period).

























Figure 1 Zyflamend’s effects on cell proliferation of PrEC, RWPE-1, LNCaP, PC3 and CWR22Rv1 cells using MTT assay. Cells were
treated ± Zyflamend at various concentrations (0, 100, 150 and 200 μg/mL) over 24, 48, 72 and 96 hr (n = 8/time period).
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CWR22Rv1 cells were cultured with RPMI 1640 medium
containing in the presence and absence of Zyflamend
(200 μg/mL) for 24 and 48 hr to demonstrate induction of
p21 expression. Cells were also exposed to Zyflamend
for 24 hr and then maintained for another 24 hr in the
absence of Zyflamend. In addition, cells were treated
with Zyflamend (200 μg/mL) for 24 hr prior to adding
cycloheximide (10 μM) to terminate protein synthesis
for an additional 0, 0.5, 1, 1.5, 2, 4 hr in the continued
presence or absence of Zyflamend (200 μg/mL) and then
harvested for protein analysis.
Western blotting
CWR22Rv1 cells were lysed in the presence of cell lysis
buffer (Cell Signaling Technology, Inc. Danver, MA).
Protein content of the lysates was quantified by BCA
protein assay kit (Pierce Biotechnology, Inc., Rockford, IL).
Lysates (20 μg) were fractioned by 8 ~ 12% SDS-PAGE and
transferred to a polyvinylidine diflouride (PVDF) mem-
brane by electroblotting. The membranes were blocked
using 5% nonfat dry milk in 0.1% Tris-buffered saline-
Table 2 Effects of individual herbal extracts or Zyflamend® on mRNA expression of class I and II histone deacetylases and relative HDAC activity
compared to controls
Control Zyflamend Rosemary Turmeric Barberry Hu Zhang Gold Thread Skull Cap Holy Basil Green Tea Ginger
Relative mRNA (n = 3)1
HDAC1 1.00 ± 0.04 0.42 ± 0.05* 0.76 ± 0.07 1.28 ± 0.07* 0.94 ± 0.04 0.92 ± 0.02 0.57 ± 0.05* 0.76 ± 0.01* 1.61 ± 0.02* 1.22 ± 0.13 0.95 ± 0.03
HDAC2 1.00 ± 0.01 0.34 ± 0.03* 0.79 ± 0.10 0.94 ± 0.15 0.67 ± 0.07* 0.70 ± 0.05 0.35 ± 0.04* 0.23 ± 0.02* 1.09 ± 0.04 0.87 ± 0.02* 0.52 ± 0.06*
HDAC3 1.00 ± 0.02 0.17 ± 0.02* 0.94 ± 0.05 0.99 ± 0.06 0.58 ± 0.17 1.09 ± 0.02 0.26 ± 0.01* 0.35 ± 0.03* 0.82 ± 0.09 0.69 ± 0.05* 0.91 ± 0.07
HDAC4 1.00 ± 0.10 0.13 ± 0.01* 1.80 ± 0.09* 1.84 ± 0.08* 1.56 ± 0.25 1.07 ± 0.05 0.59 ± 0.04* 0.47 ± 0.02* 1.52 ± 0.12* 1.35 ± 0.10 2.63 ± 0.11*
HDAC5 1.00 ± 0.06 0.63 ± 0.06* 1.21 ± 0.24 1.40 ± 0.25 1.34 ± 0.05* 1.18 ± 0.09 0.27 ± 0.35* 0.61 ± 0.02* 1.12 ± 0.13 1.16 ± 0.12 1.54 ± 0.14*
HDAC6 1.00 ± 0.03 0.20 ± 0.01* 0.70 ± 0.05* 0.81 ± 0.12 1.16 ± 0.10 1.02 ± 0.05 0.27 ± 0.01* 0.38 ± 0.02* 0.84 ± 0.03* 0.72 ± 0.13 1.22 ± 0.09
HDAC7 1.00 ± 0.16 0.39 ± 0.04* 1.18 ± 0.02 1.64 ± 0.04* 1.41 ± 0.01 1.10 ± 0.04 0.53 ± 0.09* 0.61 ± 0.03* 1.37 ± 0.09 1.47 ± 0.02* 1.78 ± 0.06*
Relative HDAC activity (n = 3), cellular location: Cytosolic Nuclear
Control Zyflamend Control Zyflamend
1.00 ± 0.05 0.72 ± 0.08* 1.00 ± 0.08 0.75 ± 0.02*
1All data is relative to control values. Relative mRNA and HDAC activity data are expressed as mean ± SEM.
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incubated in TBST containing primary antibodies over-
night at 4°C. The membrane was incubated with anti-
mouse or anti-rabbit secondary antibody conjugated with
horseradish peroxidase (HRP) (Cell Signaling Technology,
Inc. Danver, MA). Protein expression was detected with
a Pierce ECL Western Blotting detection system. Each
membrane was exposed to Hyperfilm Film (GE Healthcare,
Piscataway, NJ). Antibodies of p21, p27, p53, HDAC1-7,
Erk, phospho-Erk (Cell Signaling Technology, Inc. Danver,
MA) were used. β-actin (with anti-β-actin antibody,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was
used as the control.HDAC activity assay
CWR22Rv1 cells were lysed in the presence of cold lysis
buffer (10 mM Tris–HCl, pH 7.5, 10 mM NaCl, 15 mM
Mg2Cl2, 250 mM sucrose, 0.5% NP-40, and 0.1 mM
EGTA). Cytosolic and nuclear protein fractions were
isolated through NE-PER™ Nuclear and Cytoplasmic
Extraction Reagents (Pierce Biotechnology, Rockford, IL)
following manufacturer’s instructions and HDAC activity
assays (Cayman Chemical, Ann Arbor, MI) were per-
formed as per manufacturer’s instructions. The assay
was measured using an excitation wavelength of 340 nm
and an emission wavelength of 460 nm (FluoroCount,
Perkin Elmer Inc, Waltham, MA).Statistical analysis
The results are presented as mean ± SEM and the
mRNA results are presented as mean ± SD. For two
group comparisons, the data was analyzed by two-tailed
Student’s T-statistic. For multiple comparisons, the re-
sults were analyzed by an ANOVA followed by Tukey’s
post hoc analysis when appropriate. Differences were
considered significant at p < 0.05.Table 3 Effects of Zyflamend or TSA on cell proliferation,
protein expression of various histone deacetylases and
p21 (relative to controls)
Compounds Zyflamend (200 ug/ml) TSA (2 μM)
HDAC1 0.49 ± 0.08* 0.39 ± 0.06*
HDAC2 0.64 ± 0.10* 0.93 ± 0.06
HDAC3 1.14 ± 0.13 0.88 ± 0.17
HDAC4 0.56 ± 0.12* 0.38 ± 0.01*
HDAC7 0.62 ± 0.05* 0.68 ± 0.09*
p21 2.38 ± 0.39* 6.05 ± 0.65*
Relative cell proliferation 0.53 ± 0.11* 0.45 ± 0.04*
Values are mean ± SEM; n = 5/group. *Values with an asterisk are significantly
different from control at p < 0.05. Abbreviations: HDACs, histone deacetylase;
TSA, trichostatin A.Results
Prostate cancer cell growth and DNA synthesis are
inhibited by Zyflamend
Zyflamend inhibited growth of all PrC cell lines tested in
a time and concentration-dependent manner. At the end
of 96 hr treatment, Zyflamend (200 μg/ml) inhibited cell
growth in PrEC cells by 45%, RWPE-1 cells by 80%,
LNCaP cells by 60%, PC3 cells by 50% and CWR22Rv1
cells by 75% (Figure 1). To further confirm the reduction
of cell proliferation of CWR22Rv1 cells by Zyflamend,
BrdU assay was used for determining DNA synthesis
during the cell cycle. After treatment with Zyflamend
(24 and 96 hr), BrdU incorporation in CWR22Rv1 cells
was reduced in a time and concentration-dependent
manner (Figure 2).Zyflamend inhibits expression of HDACs
In the presence of Zyflamend, mRNA expression of all
HDACs tested (HDAC 1–7) was reduced by 30-80%,
and HDAC activity (cytosolic and nuclear extracts) was
inhibited (Table 2). When cells were treated with indi-
vidual herbal extracts, only Chinese goldthread and bai-
kal skullcap appeared to mimic the down-regulation of
mRNA observed with Zyflamend with regards to all
HDACs tested (Table 2). The effects of the extracts of
rosemary, Hu Zhang, holy basil, turmeric, green tea, bar-
berry and ginger were more variable by having mixed
effects on HDAC expression. Rosemary appeared to up-
regulate mRNA for HDAC4 and down regulate HDAC6,
turmeric upregulated HDACs 1, 4, and 7, barberry
down-regulated HDAC2 and upregulated HDAC5, holy
basil upregulated HDACs 1 and 4 and down-regulated
HDAC6, green tea upregulated HDAC7 and down-
regulated HDACs 2 and 3 and ginger upregulated HDACs
4, 5 and 7 and down-regulated HDAC2. Protein levels of
HDACs 1, 2, 4 and 7 were significantly reduced following
treatment with Zyflamend (Table 3). The universal HDAC
inhibitor TSA recapitulated the results of Zyflamend on
HDAC expression and cell proliferation (Table 3).Zyflamend-mediates the induction of cell cycle inhibitors
p21 and p27, mRNA and protein
In CWR22Rv1 cells, Zyflamend treatment induced mRNA
levels for the cell cycle inhibitors p21 and p27 (Figure 3A).
Concomitantly, protein levels of p21 were increased by as
much as 2.4-fold with Zyflamend treatment compared to
control (Figure 3B). While p27 levels also were increased,
we focused our attentions on p21 due to the robust nature
of the results and the literature linking phytonutrients
with p21 expression [36]. Our results were supported
by immuno-fluorescent imaging. 4′, 6-diamidino-2-
phenylindole (DAPI), a blue fluorescent stain that binds































Figure 3 Impact of Zyflamend on mRNA and protein expression of p21 and p27. Cells were treated with increasing concentrations of
Zyflamend (0, 40, 100, 150 and 200 μg/mL). (A) Expression of mRNA levels. (B) Expression of protein levels. The bar graph quantitates the relative
protein level of p21 ± Zyflamend at 0 and 200 μg/mL. mRNA and protein values are mean ± SEM, n = 3. Values are significantly different from
non-treatment: *p < 0.05; **p < 0.01.
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p21 protein levels. It is clear from the imaging panels that
Zyflamend increased p21 levels per cell (+72%) and in-
creased nuclear accumulation (+40%) (Figure 4). Changes
in p21 protein levels were related to increased expression
and not by inhibiting protein turnover based on experi-
ments using cycloheximide (Additional file 1). The HDAC
inhibitor TSA also increased p21 expression (Table 3).p21 silencing induces cell growth
CWR22Rv1 cells were transfected with siRNA against
p21 in the presence or absence of Zyflamend. Zyflamend
increased p21 mRNA expression in mock (p < 0.005)
and in negative control siRNA transfections (p < 0.05)
(Figure 5A) with concomitant reductions in cell number
(Figure 5B). Transfection of p21 siRNA reduced p21
mRNA in the absence or presence of Zyflamend
(Figure 5A). Comparing the mock/negative control groups
to the p21 siRNA group in the presence of Zyflamend
(closed bars), there was a reduction in p21 mRNA levels
with p21 siRNA treatment (Figure 5A) and a concomitant
increase (~51%) in cell number (Figure 5B). However, in
cells not treated with Zyflamend (open bars), cell numbers
did not change following p21 siRNA treatment (Figure 5B)
despite reduced p21 expression below the baseline, sug-



























Figure 4 Zyflamend and its effects on cellular p21 expression as dete
Cells pretreated with 200 μg/ml Zyflamend for 24 hours (right) were comp
(green) abundance per cell was calculated [(total p21 fluorescence)/(nuclei
measured within discrete nuclear regions (defined using a DAPI intensity th
units. Representative images feature magnified inlays.* p < 0.001, n = 4; **pp21 overexpression reduces cell growth
To mimic the effect of the induction of p21 by Zyflamend,
p21 was overexpressed in CWR22Rv1 cells and confirmed
by Western blot (Figure 6 insert). Both p21 overexpression
and the presence of Zyflamend reduced cell proliferation
over time (p < 0.0005) (Figure 6). The reduction of cell
proliferation by p21 overexpression was potentiated in the
presence of Zyflamend (p < 0.00005). These results were
supported, in part, by the fact that Zyflamend increases
p21 promoter activation (data not shown) using a human
p21 promoter (2.4 kb) luciferase reporter construct,
consistent with increases in mRNA and protein levels.Zyflamend-induces Erk1/2, histone 3 acetylation and
acetyl CBP/p300 expression
CBP/p300 are transcriptional co-activators that have his-
tone acetyl transferase activity (as reviewed by Marmorstein
and Trievel [37]), and it has been reported that CBP/p300
are downstream targets of extracellular signal-related
kinase (Erk) [38]. Zyflamend increased the levels of
phosphorylated Erk and acetylated CBP/p300 (Figure 7)
in a time-dependent manner with the levels of pErk
increasing prior to the increase of Ac-CBP/p300. To in-
vestigate the involvement of mitogen-activated protein
(MAP) kinases on Zyflamend-induced p21 protein ex-




































rmined by immunofluorescent imaging using CWR22Rv1 cells.
ared with control cells (left). Nuclei are shown in blue. Mean p21
count)]. To assess nuclear accumulation, p21 fluorescence was also
reshold). Data are presented as the mean ± SD in relative fluorescence
< 0.001, n = 112.
Figure 5 Impact of modifying p21 expression on cell growth in the presence or absence of Zyflamend using p21 silencing. p21 mRNA
levels (A) and cell proliferation (B) were determined in the presence or absence of Zyflamend (24 or 96 hr, respectively) in cells transfected with
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Figure 6 Effects of the overexpression of p21 on cell growth in the presence or absence of Zyflamend. CWR22Rv1 cells were transfected
with pRc/CMV (empty vector) or pRc/CMV-p21 and treated in the presence or absence of Zyflamend for 24 hr. Relative expression of p21 (protein) is
presented in the insert. Following transfection with the empty vector (pRc/CMV) or pRc/CMV-p21 (p21), cells were treated ± Zyflamend for 0–96 hr.
Cell proliferation was determined using the MTT assay. Control, open bar, Control + Zyflamend (Zyf), light grey bar; Control + pRc/CMV-p21
(p21), dark grey bar; Zyflamend + pRc/CMV-p21 (p21), black bar. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.005, †p < 0.0005,
‡p < 0.00005 and §p < 0.000005; (n = 8).












Figure 7 Zyflamend’s effects on protein expression of pErk and acetyl-CBP/p300 in a time dependent manner, and on p21
expression ± Zyflamend in the presence or absence of the HDAC inhibitor U0126. (A) CWR22Rv1 cells were treated with Zyflamend
(200 μg/mL) and the expression of p-Erk and acetyl-CBP/p300 was plotted over time (0–60 min, n = 3 for each time point). The data was analyzed
by ANOVA. Data points with different letters (p-Erk) are different at p < 0.05. With regards to Ac-CBP/p300, the only data point different from t = 0
is identified with an asterisk (*). Data are presented as the mean ± SD. (B) Western blot of p21 in CWR22Rv1 cells treated ± Zyflamend (200 μg/mL) in
the presence or absence of the HDAC inhibitor U0126 (2 μM) for 24 hr.
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p38 or c-Jun N-terminal kinase (JNK). U0126 reduced
Zyflamend-induced p21 levels (Figure 7). Since HDACs
and CBP/p300 activities affect the structure of chroma-
tin by modifying histone acetylation and thus transcrip-
tional expression of target genes such as p21, histone
acetylation was examined. Histone 3 acetylation was
significantly increased in the presence of Zyflamend
(Figure 8).
Discussion
The use of herbs and botanicals and their bioactive com-
ponents are effective inhibitors of growth, angiogenesis,metastasis and inducing apoptosis in many tumor cell
lines. Many of their molecular mechanisms of action have
been characterized in vitro [2,39,40]. While the use of
combinations of bioactive compounds appear to potenti-
ate each other’s actions [1,2], not much data exists with
herbal extracts in combination as would be common in
cultures where botanicals are used as medicinal therapies.
We previously reported that Zyflamend inhibited the
proliferation of castrate-resistant PrC cells in vitro, and
growth of androgen dependent and castrate-resistant
derived PrC tumors in vivo [9,10]. We also reported
that Zyflamend inhibited the expression of insulin-like
growth factor-1 receptor (IGF-1R) and androgen receptor
Figure 8 Zyflamend increases histone 3 acetylation. Protein level
of acetylated histone 3 was determined in CWR22Rv1 cells treated ±
Zyflamend (200 μg/ml) for 24 hr. * denotes significantly different
from control at p < 0.05. Data are presented as the mean ± SD, n = 3.
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receptor expression was recapitulated using CWR22Rv1-
derived tumors in mice treated orally with Zyflamend [9].
This is important because up regulation of IGF-1R and
androgen receptor signaling has been linked to relapse
of PrC following hormone ablation therapy [41,42]. To
broaden the growing literature on the effects of Zyflamend,
we also reported that Zyflamend inhibited HDAC ex-
pression (1 and 4) in xenograph models of androgen-
dependent and castrate-resistant PrC (in vivo), and
wanted to further investigate its impact on the expres-
sion of class I and II HDACs and one of their reported
targets the tumor suppressor gene p21 [9].
Zyflamend inhibited the growth of PrEC, RWPE-1,
LNCaP and PC3 prostate cell lines, in addition to the
castrate-resistant PrC cell line CWR22Rv1. With regards
to PrEC and RWPE-1 prostate cells, the results on
growth inhibition by Zyflamend are novel, while those
observed with LNCaP, PC3 and CWR22Rv1 cells are
consistent with results published previously [10,11], thus
validating our current results. Similar to the results pre-
sented here, all cell lines tested, in addition to normal
and non-tumorigenic prostate epithelial cells (PrEC and
RWPE-1cells, respectively), have previously been shown
to be sensitive (inhibition of proliferation) to polyphenolics,
flavonoids and various botanical extracts [43-50]. PrEC
cells represent a normal prostatic epithelial cell line and
RWPE-1 cells are a non-tumorigenic human prostate
epithelial cell line transfected with the human papilloma
virus-18. LNCaP cells are an androgen-dependent PrC
tumor cell line; while PC3 cells are androgen-independent
(PC3 cells do not have a functional androgen receptor
and cannot produce PSA). Because of our interest incastrate-resistant PrC, we focused our attention on
CWR22Rv1 cells.
Over expression of various forms of HDACs is a char-
acteristic of PrC and is associated with shorter relapse
times [51], and development of castrate-resistant PrC
has been linked to upregulation and nuclear localization
of the androgen receptor [52]. Zyflamend recapitulated
and expanded upon part of our earlier work [9] by down
regulating the expression of all HDACs tested. In
addition to HDACs 1 and 4, the down regulation of
HDAC6 is of particular interest because HDAC6 mediates
nuclear translocation of the androgen receptor via dea-
cetylation of Hsp90 in castrate-resistant PrC cells [30].
In this study, Zyflamend decreased HDAC6 expression
and concomitantly Zyflamend also decreased the expres-
sion and nuclear localization of the androgen receptor
[10]. These new data contribute to a growing number of
pathways impacted by Zyflamend, helping to explain its
multiple mechanisms of action. In an effort to identify
which extracts contributed most to the effects on inhib-
ition of HDAC expression, we observed that Chinese
goldthread and baikal skullcap recapitulated the results
observed with Zyflamend. While we cannot rule out
synergistic/antagonistic actions by the other extracts in
the preparation, these data suggest that Chinese gold-
thread and baikal skullcap are most likely the major
contributors inhibiting HDAC expression by Zyflamend.
Treatment of CWR22Rv1 cells with Zyflamend re-
sulted in increased acetylation of histone 3, a key feature
of HDAC inhibitors. Epigenetic regulation via acetylation
is important in regulating tumor suppressor genes, and
p21 is a common target for bioactive phytonutrients
[36,53]. Zyflamend consistently enhanced mRNA and
protein levels of p21 (including the nuclear fraction) in
dose- and time-dependent manners and these effects
were recapitulated by the general HDAC inhibitor TSA
(positive control). Importantly, when Zyflamend was
added to cells overexpressing p21, there was an added
reduction in cell proliferation, further suggesting the
effects of Zyflamend do not rely solely on p21 expres-
sion, but potentially involve multiple mechanisms
[3,5,8,11,14]. HDACs have been shown to be important
upstream regulators of p21 [54], and hyperacetylation of
Sp1 binding sites in the proximal promoter is a key
regulator of p21 expression [54]. HDAC1 and HDAC4 have
been reported to repress p21 expression [22,25,26,54-56].
Nuclear localization of HDAC4 is enhanced in human
tissues of castrate-resistant PrC [23] and HDAC4 has
been shown to regulate p21 expression through a Sp1-
dependent, p53-independent pathway [26].
The effects on histone 3 acetylation led us to also in-
vestigate the potential upregulation of histone acetyl
transferase activity [57] because of our findings that
Zyflamend upregulated the activation of Erk1/2. The
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regulated upstream by Erk1/2 and its downstream regula-
tor, Elk-1 [38,58]. Erk1/2-dependent phosphorylation of
Elk-1 results in interaction with p300 and increased his-
tone acetyltransferase activity [38]. In a time-dependent
manner, Zyflamend increased the expression of pErk,
followed by CBP/p300 activation [59], where it appeared
that Erk1/2 phosphorylation preceded the activation of
CBP/p300. Inhibition of Erk1/2 using the Erk inhibitor
U0126 attenuated Zyflamend-induced p21 levels. Stimula-
tion of p21 expression via upregulation of the Erk pathway
has been observed by others and these effects were simi-
larly blocked in the presence of the Erk1/2 inhibitor
U0126 [60]. While CBP/p300 has been linked to p21 ex-
pression [61,62], we have yet to fully characterize CBP/
p300’s involvement in these cells. Furthermore, while
CBP/p300 has been reported as a tumor suppressor [63],
others report opposite findings [64] as these effects maybe
tumor specific.Conclusions
In summary, Zyflamend, which is composed of ten concen-
trated herbal extracts, inhibited the growth of CWR22Rv1
cells in vitro, in part, by upregulating the tumor suppressor
protein p21. These effects occurred concomitantly with
histone acetylation, a known activator of p21 expression
and cell cycle regulator. Increased expression of p21
occurred in concert with down regulation of class I and
class II HDACs where Chinese goldthread and baikal
skullcap may have the greatest effects, along with up regu-
lation of pErk signaling and concomitant activation of
CBP/p300. These data, in addition to the data previously
published in castrate-resistant PrC cells (in vitro and
in vivo), suggest a polyherbal mixture may have utility in
helping to treat advanced forms of PrC.Additional file
Additional file 1: Zyflamend® increases p21 protein synthesis but
does not prevent degradation. A) p21 protein expression was
monitored in the presence or absence of Zyflamend® (200 ug/ml) over
48 hrs. CWR22Rv1 cells were treated with Zyflamend® for 24 hrs (+24)
after which time the cells were treated for an additional 24 hrs (+48) or
in the absence of Zyflamend® for an addition 24 hrs (-48) and p21
expression was monitored. B) p21 protein expression was monitored in the
presence of ±Zyflamend® for 24 hrs (0 hr time point). p21 protein levels
were monitored for an additional 4 hrs ±Zyflamend in the presence of
cyclohexamide.Abbreviations
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